Browse by UCL people
Group by: Type | Date
Number of items: 47.
2024
Enshaei, A;
Joy, M;
Butler, E;
Kirkwood, AA;
Messina, M;
Pavoni, C;
Morgades, M;
... Moorman, AV; + view all
(2024)
A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.
Blood Advances
, 8
(5)
pp. 1155-1166.
10.1182/bloodadvances.2023011661.
|
|
Rahman, Sunniyat;
Bloye, Gianna;
Farah, Nadine;
Demeulemeester, Jonas;
Costa, Joana R;
O'Connor, David;
Pocock, Rachael;
... Mansour, Marc R; + view all
(2024)
Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.
BLOOD
, 144
(22)
pp. 2319-2326.
10.1182/blood.2024024300.
|
 |
2023
|
El-Galaly, Tarec Christoffer;
Gaidzik, Verena I;
Gaman, Mihnea-Alexandru;
Antic, Darko;
Okosun, Jessica;
Copland, Mhairi;
Sexl, Veronika;
... Grønbæk, Kirsten; + view all
(2023)
A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care.
Hemasphere
, 7
(3)
, Article e842. 10.1097/HS9.0000000000000842.
|
|
Khan, Abdullah O;
Rodriguez-Romera, Antonio;
Reyat, Jasmeet S;
Olijnik, Aude-Anais;
Colombo, Michela;
Wang, Guanlin;
Wen, Wei Xiong;
... Psaila, Bethan; + view all
(2023)
Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies.
Cancer Discovery
, 13
(2)
pp. 364-385.
10.1158/2159-8290.CD-22-0199.
|
|
Leongamornlert, Daniel;
Gutiérrez-Abril, Jesús;
Lee, Soo Wah;
Barretta, Emilio;
Creasey, Tom;
Gundem, Gunes;
Levine, Max Fine;
... Papaemmanuil, Elli; + view all
(2023)
Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia.
Blood Advances
10.1182/bloodadvances.2022008992.
(In press).
|
2022
|
Chan, WY;
Zhu, C;
Sanchez, E;
Gupta, R;
Fielding, AK;
Khwaja, A;
Payne, EM;
(2022)
Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.
British Journal of Haematology
, 198
(3)
pp. 478-481.
10.1111/bjh.18248.
|
|
Marks, David I;
Clifton-Hadley, Laura;
Copland, Mhairi;
Hussain, Jiaull;
Menne, Tobias F;
McMillan, Andrew;
Moorman, Anthony V;
... Fielding, Adele K; + view all
(2022)
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
Lancet Haematol
, 9
(4)
e276-e288.
10.1016/S2352-3026(22)00036-9.
|
|
Marks, David I;
Kirkwood, Amy A;
Rowntree, Clare J;
Aguiar, Melanie;
Bailey, Katharine E;
Beaton, Brendan;
Cahalin, Paul;
... Fielding, Adele K; + view all
(2022)
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
Lancet Haematology
, 9
(4)
e262-e275.
10.1016/S2352-3026(22)00038-2.
|
2021
|
Creasey, T;
Barretta, E;
Ryan, SL;
Butler, E;
Kirkwood, AA;
Leongamornlert, D;
Papaemmanuil, E;
... Moorman, AV; + view all
(2021)
Genetic and genomic analysis of acute lymphoblastic leukaemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.
Haematologica
10.3324/haematol.2021.279177.
(In press).
|
|
|
Creasey, T;
Enshaei, A;
Nebral, K;
Schwab, C;
Watts, K;
Cuthbert, G;
Vora, A;
... Moorman, AV; + view all
(2021)
Single nucleotide polymorphism (SNP) array-based signature of low hypodiploidy in acute lymphoblastic leukemia.
Genes Chromosomes and Cancer
10.1002/gcc.22956.
(In press).
|
|
|
Fox, TA;
Carpenter, B;
Taj, M;
Perisoglou, M;
Nicholson, E;
Castleton, A;
Elliot, J;
... Hough, R; + view all
(2021)
Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
Leukemia & Lymphoma
, 62
(4)
pp. 1010-1012.
10.1080/10428194.2020.1855346.
|
|
Mitchell, RJ;
Kirkwood, AA;
Barretta, E;
Clifton-Hadley, L;
Lawrie, E;
Lee, S;
Leongamornlert, D;
... Fielding, AK; + view all
(2021)
IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.
Blood Advances
, 5
(17)
pp. 3322-3332.
10.1182/bloodadvances.2021004430.
|
|
|
Moorman, Anthony;
Butler, Ellie;
Barretta, Emilio;
Kirkwood, Amy A;
Schwab, Claire;
Creasey, Thomas;
Leongamornlert, Daniel A;
... Enshaei, Amir; + view all
(2021)
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
Leukemia
10.1038/s41375-021-01448-2.
(In press).
|
|
|
Paietta, E;
Roberts, KG;
Wang, V;
Gu, Z;
Buck, G;
Pei, D;
Cheng, C;
... Litzow, MR; + view all
(2021)
Molecular classification improves risk assessment in adult BCR-ABL1–negative B-ALL.
Blood
, 138
(11)
pp. 948-958.
10.1182/blood.2020010144.
|
2020
|
Aref, S;
Castleton, AZ;
Bailey, K;
Burt, R;
Dey, A;
Leongamornlert, D;
Mitchell, RJ;
... Fielding, AK; + view all
(2020)
Type-1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus.
Molecular Therapy
, 28
(4)
pp. 1043-1055.
10.1016/j.ymthe.2020.01.027.
|
|
Fielding, AK;
Goldstone, AH;
(2020)
Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL.
British Journal of Haematology
, 191
(4)
pp. 558-561.
10.1111/bjh.17166.
|
|
|
Goswami, P;
Oliva, EN;
Ionova, T;
Else, R;
Kell, J;
Fielding, AK;
Jennings, DM;
... Salek, S; + view all
(2020)
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.
Frontiers in Pharmacology
, 11
, Article 571066. 10.3389/fphar.2020.571066.
|
|
|
Goswami, P;
Oliva, EN;
Ionova, T;
Else, R;
Kell, J;
Fielding, AK;
Jennings, DM;
... Salek, S; + view all
(2020)
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.
Frontiers in Pharmacology
, 11
, Article 1308. 10.3389/fphar.2020.01308.
|
|
|
Goswami, P;
Oliva, EN;
Ionova, T;
Else, R;
Kell, J;
Fielding, AK;
Jennings, DM;
... Salek, S; + view all
(2020)
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.
Frontiers in Pharmacology
, 11
, Article 209. 10.3389/fphar.2020.00209.
|
|
|
Goswami, P;
Oliva, EN;
Ionova, T;
Else, R;
Kell, J;
Fielding, AK;
Jennings, DM;
... Salek, S; + view all
(2020)
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study.
Therapeutic Advances in Hematology
, 11
pp. 1-14.
10.1177/2040620720955002.
|
|
|
Lecat, CSY;
Besley, C;
Hough, RE;
Khwaja, A;
Furness, C;
Marks, DI;
Fielding, AK;
(2020)
Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data.
Leukemia & Lymphoma
, 61
(2)
pp. 491-493.
10.1080/10428194.2019.1672057.
|
|
Leong, S;
Inglott, S;
Papaleonidopoulou, F;
Orfinada, K;
Ancliff, P;
Bartram, J;
Carpenter, B;
... O'Connor, D; + view all
(2020)
CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.
Blood Advances
, 4
(19)
pp. 4665-4668.
10.1182/bloodadvances.2020002502.
|
|
Wilson, AJ;
Troy-Barnes, E;
Subhan, M;
Clark, F;
Gupta, R;
Fielding, AK;
Kottaridis, P;
... Khwaja, A; + view all
(2020)
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
[Letter].
British Journal of Haematology
, 190
(4)
e189-e191.
10.1111/bjh.16962.
|
2019
|
Burt, R;
Dey, A;
Aref, S;
Aguiar, M;
Akarca, A;
Bailey, K;
Day, W;
... Fielding, AK; + view all
(2019)
Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.
Blood
, 134
(17)
pp. 1415-1429.
10.1182/blood.2019001398.
|
|
Burt, R;
Warcel, D;
Fielding, AK;
(2019)
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies.
Human Vaccines & Immunotherapeutics
, 15
(3)
pp. 594-602.
10.1080/21645515.2018.1540828.
|
|
Fielding, AK;
(2019)
Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.
Hematology, the ASH Education Program
, 2019
(1)
pp. 24-29.
10.1182/hematology.2019000010.
|
|
Fielding, AK;
(2019)
En-Abl-ing treatment of “Ph-like” ALL?
Blood
, 134
(16)
pp. 1277-1278.
10.1182/blood.2019002621.
|
|
Fox, TA;
Carpenter, B;
Khwaja, A;
Halsey, R;
Grandage, V;
Mansour, MR;
Fielding, AK;
(2019)
Utility of FDG-PET/CT in Lymphoblastic Lymphoma.
Presented at: 61st ASH Annual Meeting, Orlando, FL, USA.
|
|
Gökbuget, N;
Kantarjian, HM;
Brüggemann, M;
Stein, AS;
Bargou, RC;
Dombret, H;
Fielding, AK;
... Topp, MS; + view all
(2019)
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Blood Advances
, 3
(20)
pp. 3033-3037.
10.1182/bloodadvances.2019000457.
|
|
|
Goswami, P;
Oliva, EN;
Ionova, T;
Else, R;
Kell, J;
Fielding, AK;
Jennings, DM;
... Salek, S; + view all
(2019)
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
Journal Of Comparative Effectiveness Research
, 8
(7)
pp. 523-533.
10.2217/cer-2018-0108.
|
|
|
Russell, SJ;
Babovic-Vuksanovic, D;
Bexon, A;
Cattaneo, R;
Dingli, D;
Dispenzieri, A;
Deyle, DR;
... Peng, K-W; + view all
(2019)
Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.
Mayo Clinic Proceedings
, 94
(9)
pp. 1834-1839.
10.1016/j.mayocp.2019.05.006.
|
|
Sellar, RS;
Mehra, V;
Fox, TA;
Grigg, A;
Kulasekararaj, A;
Sarma, A;
de Lavallade, H;
... Potter, VT; + view all
(2019)
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.
British Journal of Haematology
, 187
(1)
e20-e24.
10.1111/bjh.16136.
|
2018
|
Fox, T;
Chakraverty, R;
Burns, S;
Carpenter, B;
Thomson, K;
Lowe, D;
Fielding, A;
... Morris, EC; + view all
(2018)
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.
Blood
, 131
(8)
pp. 917-931.
10.1182/blood-2017-09-807487.
|
|
Mansour, MR;
He, S;
Li, Z;
Lobbardi, R;
Abraham, BJ;
Hug, C;
Rahman, S;
... Look, TA; + view all
(2018)
JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.
Journal of Experimental Medicine
, 215
(7)
, Article 1929. 10.1084/jem.20170484.
|
2017
|
Kantarjian, H;
Stein, A;
Goekbuget, N;
Fielding, AK;
Schuh, AC;
Ribera, J-M;
Wei, A;
... Topp, MS; + view all
(2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
New England Journal of Medicine
, 376
(9)
pp. 836-847.
10.1056/NEJMoa1609783.
|
|
Li, Z;
Abraham, BJ;
Berezovskaya, A;
Farah, N;
Liu, Y;
Leon, T;
Fielding, A;
... Look, AT; + view all
(2017)
APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
Leukemia
10.1038/leu.2017.75.
|
|
|
Martinelli, G;
Boissel, N;
Chevallier, P;
Ottmann, O;
Goekbuget, N;
Topp, MS;
Fielding, AK;
... Stein, A; + view all
(2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Journal of Clinical Oncology
, 35
(16)
pp. 1795-1802.
10.1200/JCO.2016.69.3531.
|
|
Rahman, S;
Magnussen, M;
León, TE;
Farah, N;
Li, Z;
Abraham, BJ;
Alapi, KZ;
... Mansour, MR; + view all
(2017)
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.
Blood
, 129
(24)
pp. 3221-3226.
10.1182/blood-2016-09-742148.
|
|
Russell, LJ;
Jones, L;
Enshaei, A;
Tonin, S;
Ryan, SL;
Eswaran, J;
Nakjang, S;
... Harrison, CJ; + view all
(2017)
Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.
Genes, Chromosomes and Cancer
, 56
(5)
pp. 363-372.
10.1002/gcc.22439.
|
|
2016
|
Aref, S;
Bailey, K;
Fielding, A;
(2016)
Measles to the Rescue: A Review of Oncolytic Measles Virus.
Viruses
, 8
(10)
10.3390/v8100294.
|
|
|
Dey, A;
(2016)
Enhancing the neutrophil-mediated anti-cancer response after oncolytic measles virus therapy in B cell malignancy: dissecting out the mechanism.
Doctoral thesis , UCL (University College London).
|
 |
|
Goekbuget, N;
Dombret, H;
Ribera, J-M;
Fielding, AK;
Advani, A;
Bassan, R;
Chia, V;
... Kantarjian, H; + view all
(2016)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.
Haematologica
, 101
(12)
pp. 1524-1533.
10.3324/haematol.2016.144311.
|
|
Gökbuget, N;
Kelsh, M;
Chia, V;
Advani, A;
Bassan, R;
Dombret, H;
Doubek, M;
... Kantarjian, H; + view all
(2016)
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.
Blood Cancer J
, 6
(9)
, Article e473. 10.1038/bcj.2016.84.
|
|
|
Gu, Z;
Churchman, M;
Roberts, K;
Li, Y;
Liu, Y;
Harvey, RC;
McCastlain, K;
... Mullighan, CG; + view all
(2016)
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
Nature Communications
, 7
, Article 13331. 10.1038/ncomms13331.
|
|
|
Kumar, AJ;
Gimotty, PA;
Gelfand, J;
Buck, G;
Rowe, JM;
Goldstone, AH;
Fielding, A;
... Loren, AW; + view all
(2016)
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.
American Journal of Hematology
, 91
(11)
pp. 1107-1112.
10.1002/ajh.24497.
|
|
|
Patel, B;
Kirkwood, AA;
Dey, A;
Marks, DI;
McMillan, AK;
Menne, TF;
Micklewright, L;
... Fielding, AK; + view all
(2016)
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.
Leukemia
10.1038/leu.2016.219.
|
|
Reyal, Y;
Kayani, I;
Bloor, AJC;
Fox, CP;
Chakraverty, R;
Sjursen, A-M;
Fielding, AK;
... Peggs, KS; + view all
(2016)
Impact of Pretransplantation F-18-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.
Biology of Blood and Marrow Transplantation
, 22
(7)
pp. 1234-1241.
10.1016/j.bbmt.2016.03.034.
|
